JP6767865B2 - ヒト補体ｃ５に結合する安定なポリペプチド - Google Patents

ヒト補体ｃ５に結合する安定なポリペプチド Download PDF

Info

Publication number
JP6767865B2
JP6767865B2 JP2016537298A JP2016537298A JP6767865B2 JP 6767865 B2 JP6767865 B2 JP 6767865B2 JP 2016537298 A JP2016537298 A JP 2016537298A JP 2016537298 A JP2016537298 A JP 2016537298A JP 6767865 B2 JP6767865 B2 JP 6767865B2
Authority
JP
Japan
Prior art keywords
polypeptide
binding
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016537298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529270A (ja
Inventor
ヨアキム・ニルソン
エーリク・ノルドリング
パトリク・ストレームベルイ
Original Assignee
スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） filed Critical スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル）
Publication of JP2016529270A publication Critical patent/JP2016529270A/ja
Application granted granted Critical
Publication of JP6767865B2 publication Critical patent/JP6767865B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
JP2016537298A 2013-08-28 2014-08-28 ヒト補体ｃ５に結合する安定なポリペプチド Active JP6767865B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350986-4 2013-08-28
SE1350986 2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020113725A Division JP2020172505A (ja) 2013-08-28 2020-07-01 ヒト補体ｃ５に結合する安定なポリペプチド

Publications (2)

Publication Number Publication Date
JP2016529270A JP2016529270A (ja) 2016-09-23
JP6767865B2 true JP6767865B2 (ja) 2020-10-14

Family

ID=51539238

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016537298A Active JP6767865B2 (ja) 2013-08-28 2014-08-28 ヒト補体ｃ５に結合する安定なポリペプチド
JP2020113725A Pending JP2020172505A (ja) 2013-08-28 2020-07-01 ヒト補体ｃ５に結合する安定なポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020113725A Pending JP2020172505A (ja) 2013-08-28 2020-07-01 ヒト補体ｃ５に結合する安定なポリペプチド

Country Status (29)

Country Link
US (1) US9994626B2 (enExample)
EP (2) EP3811961B1 (enExample)
JP (2) JP6767865B2 (enExample)
KR (1) KR102446636B1 (enExample)
CN (1) CN105658228B (enExample)
AU (1) AU2014314222B2 (enExample)
BR (1) BR112016003142A2 (enExample)
CA (1) CA2926976C (enExample)
CY (1) CY1123732T1 (enExample)
DK (1) DK3038633T3 (enExample)
ES (1) ES2842105T3 (enExample)
HR (1) HRP20210013T1 (enExample)
HU (1) HUE052613T2 (enExample)
IL (1) IL244218A (enExample)
LT (1) LT3038633T (enExample)
MX (1) MX382140B (enExample)
MY (1) MY173804A (enExample)
NZ (1) NZ718153A (enExample)
PH (1) PH12016500371A1 (enExample)
PL (1) PL3038633T3 (enExample)
PT (1) PT3038633T (enExample)
RS (1) RS61347B1 (enExample)
RU (1) RU2733897C2 (enExample)
SA (1) SA516370622B1 (enExample)
SG (1) SG11201602679VA (enExample)
SI (1) SI3038633T1 (enExample)
SM (1) SMT202100006T1 (enExample)
UA (1) UA117933C2 (enExample)
WO (1) WO2015028558A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020180133A (ja) * 2013-08-28 2020-11-05 アフィボディ・アーベー 変異した骨格を有する結合ポリペプチド

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102149028B1 (ko) * 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
WO2015028558A1 (en) * 2013-08-28 2015-03-05 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement c5
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
IL307197B2 (en) 2017-07-11 2026-03-01 Alexion Pharma Inc Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
WO2022171892A1 (en) * 2021-02-15 2022-08-18 Affibody Ab New her2-binding polypeptide
EP4426348A4 (en) * 2021-11-01 2025-10-01 Ipc Res Llc ADMINISTRATION OF C5-BINDING PROTEINS
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
ATE449791T1 (de) 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
MXPA04001301A (es) 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
CA2579635A1 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
DK1991275T3 (en) * 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
DE08786222T1 (de) 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
ES2373832T3 (es) * 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
BR112013000452A2 (pt) 2010-07-09 2020-02-11 Affibody Ab Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
KR102149028B1 (ko) 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
JP6577868B2 (ja) 2012-12-19 2019-09-18 アフィボディ・アーベー 新規ポリペプチド
US9982022B2 (en) * 2013-08-28 2018-05-29 Affibody Ab Binding polypeptides having a mutated scaffold
WO2015028558A1 (en) * 2013-08-28 2015-03-05 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement c5

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020180133A (ja) * 2013-08-28 2020-11-05 アフィボディ・アーベー 変異した骨格を有する結合ポリペプチド

Also Published As

Publication number Publication date
EP3811961B1 (en) 2025-08-20
CN105658228A (zh) 2016-06-08
CA2926976A1 (en) 2015-03-05
HRP20210013T1 (hr) 2021-04-02
RU2733897C2 (ru) 2020-10-09
SMT202100006T1 (it) 2021-03-15
SI3038633T1 (sl) 2021-05-31
DK3038633T3 (da) 2021-01-11
MY173804A (en) 2020-02-24
PL3038633T3 (pl) 2021-07-19
RU2016111115A (ru) 2017-10-03
ES2842105T3 (es) 2021-07-12
KR102446636B1 (ko) 2022-09-23
RS61347B1 (sr) 2021-02-26
SA516370622B1 (ar) 2018-12-23
AU2014314222B2 (en) 2018-05-24
BR112016003142A2 (pt) 2017-10-17
EP3811961A1 (en) 2021-04-28
CN105658228B (zh) 2020-02-07
WO2015028558A1 (en) 2015-03-05
LT3038633T (lt) 2021-03-25
RU2016111115A3 (enExample) 2018-04-25
SG11201602679VA (en) 2016-05-30
US20160311870A1 (en) 2016-10-27
EP3038633B1 (en) 2020-10-14
AU2014314222A1 (en) 2016-04-21
IL244218A0 (en) 2016-04-21
PH12016500371B1 (en) 2016-05-02
KR20160048121A (ko) 2016-05-03
NZ718153A (en) 2022-05-27
JP2016529270A (ja) 2016-09-23
PH12016500371A1 (en) 2016-05-02
HUE052613T2 (hu) 2021-05-28
MX2016002397A (es) 2016-09-08
HK1225656A1 (en) 2017-09-15
JP2020172505A (ja) 2020-10-22
US9994626B2 (en) 2018-06-12
CA2926976C (en) 2023-11-28
BR122023020080A2 (pt) 2023-12-26
CY1123732T1 (el) 2021-10-29
MX382140B (es) 2025-03-13
IL244218A (en) 2017-11-30
UA117933C2 (uk) 2018-10-25
PT3038633T (pt) 2021-01-14
RU2020128977A (ru) 2021-11-30
EP3038633A1 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
JP2020172505A (ja) ヒト補体ｃ５に結合する安定なポリペプチド
JP6719438B2 (ja) ヒト補体ｃ５に結合するポリペプチド
JP7684803B2 (ja) 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
US11098096B2 (en) Alzheimer Aβ peptide binding polypeptide
JP2016535061A (ja) 変異した骨格を有する結合ポリペプチド
JP2017125013A (ja) Ｖｅｇｆｒ１抗体についての治療的使用
HK40050539B (en) Stable polypeptides binding to human complement c5
HK40050539A (en) Stable polypeptides binding to human complement c5
HK1225656B (en) Stable polypeptides binding to human complement c5
BR122023020080B1 (pt) Polipeptídeos e compostos de ligação a c5 do complemento humano

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20190319

A256 Written notification of co-pending application filed on the same date by different applicants

Free format text: JAPANESE INTERMEDIATE CODE: A2516

Effective date: 20190319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200701

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200701

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200708

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200714

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200908

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200918

R150 Certificate of patent or registration of utility model

Ref document number: 6767865

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250